USPTO will not appeal MDCO’s victory on the Angiomax patent extension: http://finance.yahoo.com/news/The-Medicines-Company-iw-3076217221.html?x=0&.v=1 MDCO’s PR was issued after the market close, but the actual decision occurred earlier, as evidenced by the 1-day chart: ih.advfn.com/p.php?pid=staticchart&s=N%5EMDCO&p=0&t=16